<DOC>
	<DOCNO>NCT02237521</DOCNO>
	<brief_summary>Patients end-stage renal disease ( ESRD ) high prevalence impair glucose metabolism . The pathophysiological cause uncertain , disturbance secretion , elimination effect glucagon , insulin two incretin hormone glucagon-like peptide-1 ( GLP-1 ) glucose-dependent insulinotropic polypeptide ( GIP ) , probably play important role . Our research group previously find dialysis patient without type 2 diabetes mellitus ( T2DM ) reduce incretin effect inability suppress glucagon meal - two early pathophysiological characteristic patient T2DM normal kidney function . The aim project provide detailed description mechanism underlie ( patho ) physiological effect incretin hormone patient ESRD . We plan investigate mentioned disturbance fast hyperglycaemic condition use incretin infusion glucose clamp . Furthermore , stable isotopic tracer use determine effect incretin hormone endogenous glucose handling . We hypothesise effect incretin hormone ESRD reduce respect healthy control subject .</brief_summary>
	<brief_title>The Effect Incretin Hormones Endocrine Pancreatic Function During Hyperglycemia End-stage Renal Disease</brief_title>
	<detailed_description>The effect incretin hormone endocrine pancreatic function uremic environment explore fasting hyperglycemic condition three randomise examination day . At precede screen day , oral glucose tolerance test ( OGTT ) dual energy x-ray absorptiometry ( DXA ) scan perform determine glucose tolerance distribution muscle adipose tissue . The study carry three separate day differ respect hormone infuse : GLP-1 , GIP placebo ( saline ) double blind . The patient meet overnight fast infusion one hormone initiate . At time label glucose infused determine endogenous hepatic glucose production . A glucose infusion adjust accord frequent plasma glucose measurement maintain fast glucose level . After 2 hour steady state tracer achieve 2 hour hyperglycemic clamp , 3 mmol/l fast glucose concentration start . The tracer infusion continue hyperglycemia . After 4 hour clamp arginine bolus administer measure ability increase secretion insulin glucagon .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>Inclusion Criteria ( Endstage renal disease ) : Chronic hemodialysisdependent uremia 3 month Inclusion Criteria ( Healthy control ) : Normal kidney function Fasting plasma glucose ≥ 6.1 mmol/l 2h plasma glucose ≥ 7.8 ingestion 75 gram glucose Admittance hospital Anemia ( Hb &lt; 6.0 mmol/l ) Ongoing treatment drug interfere glucose metabolism include steroid calcineurin inhibitor Bowel resection large abdominal surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Incretin hormone</keyword>
	<keyword>End-stage renal disease</keyword>
	<keyword>ESRD</keyword>
	<keyword>GLP-1</keyword>
	<keyword>GIP</keyword>
	<keyword>Insulin</keyword>
	<keyword>Glucagon</keyword>
</DOC>